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PURPOSE. Glaucoma is a complex disease with major risk factors including advancing age and
increased intraocular pressure (IOP). Dissecting these earliest events will likely identify new
avenues for therapeutics. Previously, we performed transcriptional profiling in DBA/2J (D2)
mice, a widely used mouse model relevant to glaucoma. Here, we use these data to identify
and test regulators of early gene expression changes in DBA/2J glaucoma.
METHODS. Upstream regulator analysis (URA) in Ingenuity Pathway Analysis was performed to
identify potential master regulators of differentially expressed genes. The function of one
putative regulator, mesenchyme homeobox 2 (Meox2), was tested using a combination of
genetic, biochemical, and immunofluorescence approaches.
RESULTS. URA identified Meox2 as a potential regulator of early gene expression changes in the
optic nerve head (ONH) of DBA/2J mice. Meox2 haploinsufficiency did not affect the
characteristic diseases of the iris or IOP elevation seen in DBA/2J mice but did cause a
significant increase in the numbers of eyes with axon damage compared to controls. While
young mice appeared normal, aged Meox2 haploinsufficient DBA/2J mice showed a 44%
reduction in MEOX2 protein levels. This correlated with modulation of age- and disease-
specific vascular and myeloid alterations.
CONCLUSIONS. Our data support a model whereby Meox2 controls IOP-dependent vascular
remodeling and neuroinflammation to promote axon survival. Promoting these earliest
responses prior to IOP elevation may be a viable neuroprotective strategy to delay or prevent
human glaucoma.
Keywords: Meox2, axon degeneration, DBA/2J, myeloid cells, vasculature, gene expression
Glaucoma, the leading cause of irreversible blindnessworldwide, is an amalgam of diseases that involve retinal
ganglion cell (RGC) death and degeneration of the optic
nerve.1,2 Major risk factors include age and elevated intraocular
pressure (IOP), but the molecular basis of how these factors
contribute to glaucomatous damage is not well understood. In
human and nonhuman primate glaucoma, increased IOP has
been shown to cause changes in the optic nerve head (ONH),
the area of convergence of RGC axons exiting the back of the
eye.3–7 These changes include increased translaminar pressure
gradient, distortion of ONH biomechanical support, and excess
deposition of extracellular matrix.1,8–12 Determining whether
these changes are primary or secondary and damaging or
beneficial is challenging if one is studying human subjects
alone.
Animal models are widely used to study the earliest events in
a complex disease like glaucoma. Multiple models relevant to
ocular hypertension (OHT) and glaucoma have shown that
some of the earliest changes in the ONH involve astrocytes and
microglia.13–15 Among other things, these glial cells activate
immune-like processes that are likely to damage ONH
structures including the neurovascular unit (NVU).16–18 Previ-
ous studies have suggested the decline in blood vessel health in
the optic nerve may contribute to glaucoma, and similar
changes have been seen in other neurodegenerative diseases
such as Alzheimer’s disease, Parkinson’s disease, and Hunting-
ton’s disease.19,20 However, which early neurovascular and glial
responses are beneficial or damaging is still unclear.
Gene expression data provide a sensitive assay of molecular
changes that can elucidate mechanisms of disease in tissue
prior to overt morphologic changes. The ONH is an area that
undergoes unique stress in OHT, and gene expression changes
will prove instructive in finding the molecular mechanisms of
OHT-induced glaucoma. Multiple studies, including our own,
have profiled ONHs and retinas from different animal and cell
models to identify genes and pathways that are modified in
glaucoma.21–28 These studies have used multiple models
including mice, rats, primates, and human ONH astrocytes
and have suggested glial-, immune-, and vascular-relevant
changes in response to OHT.
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In our studies, we have primarily focused on DBA/2J (D2)
mice as they show asynchronous age- and IOP-dependent RGC
loss that mimics hallmarks of human glaucoma.29–31 Previously,
microarray data of ONH and retina tissue from D2 and
D2.Gpnmbþ (a substrain of D2 that does not develop IOP
elevation and RGC loss) and hierarchical clustering identified
seven stages of glaucoma progression (stages 1a, 1b, 1c, 2, 3, 4,
and 5) that were molecularly defined and compared to
conventional morphologic analysis of axon damage in the
optic nerve.27,32 Stages 1a through 1c and stage 2 are
considered to represent early gene expression changes that
precede axon damage and other pathological signs of
glaucoma.27,32 Previous analyses and functional testing of this
gene expression dataset have identified the activation of the
complement cascade and the endothelin system as early events
in D2 glaucoma.27
Here, we now reanalyze our transcriptional profiling dataset
focusing on identifying key upstream regulators of the
differentially expressed genes in these early molecular stages.
We used upstream regulator analysis (URA) in Ingenuity
Pathway Analysis (IPA) to identify putative regulators of early
responses to OHT. URA identifies a cascade of upstream
transcriptional regulators that can explain the observed gene
expression changes in a given dataset. We identified mesen-
chyme homeobox 2 (Meox2) as a predicted regulator of
multiple genes differentially expressed in early stages of D2
glaucoma. We show that Meox2 haploinsufficiency reduces
MEOX2 protein levels by approximately 44% and increases the
number of eyes with axon damage compared to controls,
particularly in female mice. These findings suggest that Meox2
plays a beneficial role in response to OHT. Further, we provide
data to support a model whereby vascular remodeling of the
retina and myeloid cell activation in the ONH are modified by
Meox2 haploinsufficiency.
METHODS
Functional Analysis and Gene Set Enrichment of
Differentially Expressed Genes
Data were previously generated by Howell et al.27,28,32 Stage 1c
genes (11,068 genes) were significantly differentially expressed
(false detection rate [FDR] < 0.05) and processed through
Ingenuity Pathway Analysis (IPA) (Qiagen, Inc., Redwood City,
CA, USA). Fold change threshold was set at 61.5. Resultant
genes were processed for URA in IPA. This analysis also
provided informative mechanistic networks based upon
previously generated citations to create a directional map of
the genes in the dataset affected by the regulator. Mechanistic
network associations were available for both Nfatc1 and
Meox2 and there were no associations for Rcan1, Ikfz1, and
Htatip2. Mechanistic network pathway-associated genes were
processed through DAVID v6.8 (Database for Annotation,
Visualization and Integrated Discovery) for KEGG Pathway
analysis.33
Gene ontology (GO) terms were also assessed through
DAVID v6.8. The number of genes associated with each term
was generated and the log of the P value was calculated
(Benjamini corrected P < 0.05). Expression fold change of
chosen genes was determined by the Glaucoma Discovery
Platform (GDP).27,28 K-means analysis was generated using
genes differentially expressed (DE) across stage 2 through 5
data with basic R implementation (R Development Core Team,
version 3.6.0) for six distinct clusters (k-means ¼ 6). Meox2
was clustered within group 3, where the associated genes were
pooled for further analysis. Group 3 clustered genes were
processed for KEGG Pathway and GO term analysis as
previously described (Benjamini corrected P < 0.05).
Mouse Strains, Breeding, and Cohort Generation
All experiments involving mice were conducted in accordance
with policies and procedures described in the Guide for the
Care and Use of Laboratory Animals of the National Institutes
of Health and were approved by the Institutional Animal Care
and Use Committee at The Jackson Laboratory. Experiments
also adhered to the ARVO Statement for the Use of Animals in
Ophthalmic and Vision Research. All mice were bred and
housed in a 14/10-hour light/dark cycle. All D2 mice were
obtained either from The Jackson Laboratory production
facility (JAX stock #000671; The Jackson Laboratory, Bar
Harbor, ME, USA) or from the Howell or John Lab research
colony. D2 mice are homozygous for two gene mutations,
GpnmbR150X and Tyrp1isa, and develop elevated IOP, iris
stromal atrophy, and glaucoma-mediated RGC death. However,
D2 mice homozygous for Gpnmb (Gpþ) do not develop
elevated IOP or glaucoma and exhibit only mild iris stromal
atrophy. Therefore D2.Gpþ mice (JAX stock #007048; The
Jackson Laboratory) were used as a genetically matched
control for D2 mice.
To create experimental strains, D2 mice were backcrossed
with B6.129S4-Meox2CreSor (JAX stock #003755; The Jackson
Laboratory) for more than six generations and then inter-
crossed, creating D2 mice that are heterozygous for the
insertion of the cre-recombinase gene that disrupts the
transcription of the Meox2 gene, creating a Meox2 null allele
(Mxþ/). D2.GpþMxþ/ were created by crossing D2.Mxþ/
mice with D2.Gpþ mice and then intercrossing offspring. D2
and D2.Mxþ/ cohorts were generated by aging both males and
females to 4, 8, 10.5, and 12 months with cohorts of n¼ 40 or
more. D2.Gpþ and D2.GpþMxþ/ cohorts were generated by
aging both males and females to 4 and 10.5 months with
cohorts of n ¼ 40 or more. Specific numbers of mice per
experiment are listed with each experiment.
Slit-Lamp Examination and IOP Measurements
D2 mice develop an iris pigment disease leading to increased
OHT and resulting in axon damage and degeneration. Both
males and females were evaluated for iris disease progression at
8 months using previously described methods (female D2 and
D2.Mxþ/ n¼ 30, 22, respectively; male D2 and D2.Mxþ/ n¼
16, 18, respectively).30 IOP was measured at 8, 10.5, and 12
months of age using previously described methods (8 months:
female D2 n¼ 27, D2.Mxþ/ n¼ 39; male D2 n¼ 33, D2.Mxþ/
n¼40) (10.5 months: female D2 n¼24, D2.Mxþ/n¼30; male
D2 n ¼ 20, D2.Mxþ/ n ¼ 46) (12 months: female D2 n ¼ 20,
D2.Mxþ/ n ¼ 22; male D2 n ¼ 22, D2.Mxþ/ n ¼ 46).34,35
Statistical analysis was performed using a 2-way ANOVA.
Blood Pressure Measurements
Blood pressure was recorded using a blood pressure analysis
system (BP-2000 Series II; Visitech Systems, Inc., Apex, NC,
USA) as previously described with a few modifications.36 Mice
acclimated to the procedure room for 1 week prior to any
blood pressure readings. Blood pressure was then recorded for
a total of 5 days; the first 3 days of readings were used as an
acclimation period and therefore no data from these days were
included in analysis. The final 2 days of recordings were
analyzed. Recordings were taken at the same time each day to
control for circadian rhythm changes throughout the day.
Additionally, the investigator was blinded to genotype while
performing the readings. Each machine accommodated six
Meox2 Regulates Axonal Damage in DBA/2J Glaucoma IOVS j August 2019 j Vol. 60 j No. 10 j 3284
Downloaded from iovs.arvojournals.org on 10/15/2019
mice in restraining units and had a warming plate that
maintained temperature at 388C. Tail cuffs were placed on
the base of the tail of each mouse and went through 30 rapid
cycles of computer-automated inflation and deflation. Blood
pressure was detected by a photoresistor cell below each tail
and recorded by a computer using BP-2000 Blood Pressure
Analysis software, which reported systolic and diastolic
pressure and pulse. A recording was considered successful if
a systolic, diastolic, and pulse reading were all reported for the
cycle. For a mouse to be included in analysis, there had to be a
minimum of 10 successful cycles. Then, each component of
the cycle was averaged over the 2 days for each mouse. The
mice tested were approximately 7 months of age and the
sample sizes for each condition were as follows: D2 female,
male n¼ 11, 6; D2.Mxþ/ female, male n¼ 10, 6. Significance
between conditions was determined using a 2-way ANOVA.
Axon Damage Assessment
Intracranial portions of optic nerves were processed and
analyzed as previously described.31,37–39 Optic nerves were
fixed in Smith-Rudt (0.8% paraformaldehyde, 1.2% glutaralde-
hyde in 0.1 M phosphate buffer) for 16 hours, dissected free
from the brain, processed, and embedded in plastic. One-
micrometer-thick sections were then cut and stained with
paraphenyldiamine (PPD). PPD darkly stains myelin sheaths
and axoplasm of diseased or dying axons and lightly stains
healthy axons. Two blinded investigators determined the
degree of nerve damage as previously described.37,38,40,41 In
rare instances of a disagreement, a third investigator deter-
mined the degree of axon damage and the most common
category among the three investigators was assigned. Nerves
with no or early glaucoma (NOE) have no detectable
glaucomatous damage and are indistinguishable from D2.Gpþ
nerves. Moderately (MOD) affected nerves have readily
detectable degenerating axons (approximately 50% axon loss)
as marked by darkly stained axoplasm. Severely (SEV) affected
nerves have >50% axon loss and prominent gliosis. This
method of assessing nerve damage has been previously
validated by multiple methods including axon transport,
pattern electroretinogram (PERG), axon counts, RGC soma
counts, and hematoxylin and eosin staining.15,40–43 Sample
sizes for each experiment were as follows for females and
males, respectively: 4 months D2, n¼47, 50; 8 months D2, n¼
65, 46; 10.5 months D2, n¼ 52, 61; 12 months D2, n¼ 34, 36;
4 months D2.Mxþ/, n¼35, 23; 8 months D2.Mxþ/, n¼58, 49;
10.5 months D2.Mxþ/, n¼ 50, 43; and 12 months D2.Mxþ/, n
¼ 40, 61. To determine whether axon damage profiles were
significantly different between sex, age, or genotype, v2 tests
were performed comparing each damage level assignment per
condition.
Western Blotting of Retinas
Following ketamine/xylazine anesthesia, mice were perfused
with phosphate-buffered saline (PBS) and retinas extracted.
Upon removal of the eye from the animal, retinas were
dissected from the globe and immediately placed on ice in 50
lL radioimmunoprecipitation assay (RIPA) buffer. Retinal tissue
was sonicated in the RIPA buffer for 10 seconds followed by 30
seconds on ice, three total intervals per tissue. Protein
concentration was confirmed via Bio-Rad’s DC Assay protocol
(Hercules, CA, USA). Protein samples were separated by SDS-
PAGE gel electrophoresis and transferred to nitrocellulose
membrane. Samples were incubated with primary antibody at
48C overnight. Prior to using horseradish peroxidase (Milli-
pore, Temecula, CA, USA) as a secondary antibody, samples
were blocked in 5% nonfat dried milk diluted in 0.1% PBS-
Tween. For detection, membranes were treated with the
Amersham ECL Western blotting analysis system (GE Health-
care, Chicago, IL, USA) and imaged via chemiluminescence on
Azure Biosystems (Dublin, CA, USA) cSeries Capture software.
The primary antibodies used for immunoblotting were
monoclonal anti-MEOX2 (predicted band size: 33.6 kilodaltons
[kDa], 1:1000; Sigma-Aldrich Corp., St. Louis, MO, USA) and
anti-GAPDH (glyceraldehyde 3-phosphate dehydrogenase)
(predicted band size: 35.8 kDa, 1:1000; Abcam, Cambridge,
MA, USA). Blots were stripped after MEOX2 assessment and
prior to GAPDH assessment (loading control) using standard
procedures.
Immunofluorescence of Optic Nerve Heads
Female mice were killed by cervical dislocation, their eyes
enucleated and placed in 4% paraformaldehyde (PFA) over-
night. Following fixation, eyes were placed in a 30% glucose
gradient and frozen in optimal cutting temperature (OCT)
compound, and ONHs were cryosectioned at 10-lm thickness.
For immunostaining against vascular-associated proteins,
one section per eye was used to constitute cohorts: 4 months
D2, n ¼ 6; 8 months D2, n ¼ 4; 10.5 months D2, n ¼ 6; 4
months D2.Mxþ/, n ¼ 6; 8 months D2.Mxþ/, n ¼ 4; 10.5
months D2.Mxþ/, n¼4; 4 months D2.Gpþ, n¼3; 10.5 months
D2.Gpþ, n ¼ 6; 4 months D2.GpþMxþ/, n ¼ 6; 10.5 months
D2.GpþMxþ/, n ¼ 6. ONH sections were brought to room
temperature (RT), pretreated with H2O at 378C for 3 minutes,
then treated with 0.5 mg/mL pepsin (Sigma-Aldrich Corp.) in
0.2 N HCl at 378C for 10 minutes. Sections were then washed
twice with 13 PBS for 10 minutes at RT and then incubated
with primary antibody (rabbit anti-laminin [1:300] L9393;
Sigma-Aldrich Corp.) and goat anti-CD31 [1:40]; MAB3628;
R&D Biosystems, Minneapolis, MN, USA) diluted with 10%
normal donkey serum in PBT (13 PBS þ 1% Triton X-100)
overnight at 48C. Sections were then washed three times with
PBT for 10 minutes at RT and then incubated with secondary
antibody (donkey anti-rabbit AF488 [1:800]; A-21206; Thermo-
Fisher Scientific [Waltham, MA, USA] or donkey anti-goat
AF594 [1:800]; A-11058; ThermoFisher Scientific) diluted in
PBT at RT for 4 hours. Following secondary incubation,
sections were washed three times with 13 PBS for 10 minutes
at RT, incubated with 4’,6-diamidino-2-phenylindole (DAPI)
(1:1000) diluted in 13 PBS for 20 minutes, then washed once
with 13 PBS for 5 minutes at RT. Following immunostaining,
slides were mounted with Aqua Poly-Mount (Polysciences,
Warrington, PA, USA).
For immunostaining against non–vascular-associated pro-
teins, one section per eye was used to constitute cohorts: 4
months DBA/2J, n¼ 5, 8 months DBA/2J, n¼ 10, 10.5 months
DBA/2J, n¼ 6; 4 months D2.Mxþ/, n¼ 7; 8 months D2.Mxþ/,
n¼ 11; 10.5 months D2.Mxþ/, n¼ 4; 4 months D2.Gpþ, n¼ 3;
10.5 months D2.Gpþ, n ¼ 6; 4 months D2.GpþMxþ/, n ¼ 6;
10.5 months D2.GpþMxþ/, n¼ 7. ONH sections were brought
to RT, washed once with PBT for 15 minutes, and then
incubated with primary antibody (goat anti-IBA1 [1:200];
ab5076; Abcam) in 10% normal donkey serum in PBT ON at
48C. The secondary antibody and remaining steps were the
same as for vascular-related proteins listed above.
Images of immunofluorescence (IF) assays were obtained
with consistent exposure times per channel across all samples.
The exposure time for each sample was determined by taking
20 blinded samples, finding the best exposure by the ‘‘auto-
exposure’’ function in the ZEN Pro program (ZEISS, Munich,
Germany), and finding the median exposure time per channel
between the 20 blinded samples. For myeloid cell number
quantification, the area considered to be the ONH was the area
from the sclera and down 200 lm and to the outer margins.
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This area was measured, drawn, and calculated using ImageJ
(National Institutes of Health, Bethesda, MD, USA). Once the
area was determined, colocalization of DAPI and IBA1 staining
indicated a positive myeloid cell. Cell number was calculated
and reported as a cell number per area. Significance between
cohorts was determined by 2-way ANOVA.
Immunofluorescence of Whole Retinas
Following ketamine/xylazine anesthesia, mice were perfused
with PBS. Eyes were enucleated and immersion fixed in 4%
paraformaldehyde and processed as previously described.44
Briefly, eyes were hemisected and retinas dissected under a
stereomicroscope (Nikon SMZ800, Tokyo, Japan), permeabi-
lized with 1% Triton X-100 in PBS, blocked with 10% normal
donkey serum in 0.1% Triton X-100 in PBS, and incubated with
the following primary antibodies at 48C overnight: goat anti-
type IV collagen (1:40; EMD Millipore, Darmstadt, Germany)
and rabbit anti-Iba1(1:200; Wako Chemicals USA, Richmond,
VA, USA).
After washing with 0.1% Triton X-100 in PBS (3 3 15
minutes), retinas were incubated with the appropriate
fluorophore-conjugated secondary antibodies (1:500; Life
Technologies, Carlsbad, CA, USA) at 48C overnight. After
another washing with 0.1% Triton X-100 in PBS, four or five
radial cuts were made in the retinas, from the edge toward the
ONH, ganglion cell layer up, for flat mounting in Aqua-Poly/
Mount (Polysciences). Imaging was performed using the TCS
SP8 confocal laser scanning microscope (Leica, Wetzlar,
Germany), and then processed with ImageJ. All images were
taken from the peripheral retina, and the total vascular area per
image was assessed using AngioTool software.45 Using standard
parameters described by AngioTool, the area covered by a
vascular network was calculated for each image.45 Four images
from each retina were assessed within a cohort, and statistics
were generated by averaging all areas/eye for n ¼ 1.
RESULTS
Meox2 Is Predicted to Be an Upstream Regulator of
Responses to Ocular Hypertension
To identify putative regulators of early gene expression
changes, URA was performed on genes DE (FDR < 0.05, fold
change > þ1.5 or < 1.5) in stage 1c (Supplementary Table
S1). The top five transcription factors were Htatip2, Nfatc1,
Rcan1, Meox2, and Ikfz1 (Fig. 1A). These transcription factors
are predicted to directly regulate between 34 and 6 genes in
stage 1c (Fig. 1B; Supplementary Table S2). Expression of these
transcription factors steadily increased from stage 1a to stage
1c, suggesting their upregulation may have downstream effects
on multiple target genes and disease progression (Fig. 1C).
Only two of the top five transcription factors (Nfatc1 and
Meox2) were predicted by IPA to have associated mechanistic
networks (i.e., networks of genes that are predicted by the
URA to explain patterns in the gene expression data). The
Nfatc1 network contained 653 genes (Supplementary Table S3)
while the Meox2 network contained 364 genes (Fig. 1D;
Supplementary Table S4). The Nfatc1 and Meox2 mechanistic
networks showed overlapping enriched KEGG pathways
including cytokine–cytokine receptor interaction, PI3K-AKT
signaling pathway, osteoclast differentiation, phagosome, focal
adhesion, and ECM–receptor interactions (Figs. 1E, 1F), which
suggested a possible role for both genes in regulating
inflammatory and vascular responses. Given the similarity of
the predicted functions of the Nfatc1 and Meox2 mechanistic
networks, previous work on Nfatc1 and related genes such as
calcineurin in RGC degeneration, and the novelty of the
predicted role for Meox2 in glaucoma, we chose to prioritize
Meox2 for further study.46–50
Meox2 first becomes significantly upregulated in stage 1c
(Fig. 1C). Therefore, to further investigate the role of Meox2,
we identified the GO terms enriched in stage 1c that were
assigned to Meox2. Three enriched GO terms met this
criterion: ‘‘angiogenesis,’’ ‘‘positive regulation of transcription
from RNA pol II promoter,’’ and ‘‘transcription DNA-tem-
plated’’ (P¼ 1.373 107, P¼ 8.973 107, and P¼ 4.263 105,
respectively) (Fig. 2A). Angiogenesis, the most significant term,
is a GO term associated at multiple molecular stages of
glaucoma (Fig. 2B). Angiogenesis genes upregulated in stage 1c
show a comparable gene expression profile across the
molecular stages of disease to Meox2 (Fig. 2C).
To further understand possible mechanism(s) by which
Meox2 contributes to D2 glaucoma, k-means clustering was
performed to identify genes that respond similarly across the
molecular stages of disease. K-means clustering (k ¼ 6) was
performed on a set of 4137 genes that were DE across stages 2
through 5. We selected these genes because Meox2 is first DE
in stage 1c (Fig. 1) and so we hypothesized that the
downstream responders to Meox2 would be present in stages
2 through 5. Five clusters of genes were identified (group 6 is
considered an unclustered group, Fig. 3A). Meox2 clustered
with genes in group 3. Genes within group 3 were then
examined by KEGG Pathway analysis. Meox2 is not yet
associated with a KEGG pathway, but genes within group 3
were enriched for lysosome, phagosome, other glycan
degradation, and osteoclast differentiation (Fig. 3B). These
pathways are associated with inflammation and myeloid cell
activity. In support of this, GO term enrichment showed that
group 3 genes were enriched for extracellular exosome,
lysosome, and external side of plasma membrane (Fig. 3C).
These GO terms were similar to those identified by IPA in the
Meox2 mechanistic network (Fig. 1F). Genes in these enriched
KEGG pathways that also had myeloid-related GO terms
included Trem2, Tyrobp, and Itgax (Cd11c) and, as predicted
by the k-means analyses, showed a similar pattern of gene
expression across the molecular stages of disease as Meox2
(Fig. 3D). Additionally, the genes within the GO term
‘‘extracellular exosome’’ included basement membrane and
transport genes such as Itgb2, Itgb3, Timp2, and Ctsz (Fig. 3E).
Collectively, our data suggest that Meox2 is mediating early
processes in the ONH involving interactions between myeloid
cells (that may involve resident microglia, monocytes, and/or
macrophages) and neurovascular-related cells.
Meox2 Haploinsufficiency Does Not Cause Overt
Changes to Vasculature or Myeloid Cells in ONH or
Retina of Young DBA/2J Mice
Mice deficient in Meox2 (Meox2/) are embryonic lethal due
to a variety of phenotypes including abnormal vascular
development; however, previous studies by us and others
have shown that Meox2 haploinsufficiency can modify
phenotypes in other neurodegenerative disease models.51,52
Given its role in development, we assessed ONHs and retinas
in young Meox2 haploinsufficient D2s and controls. We first
performed a Western blot on the retinas of young D2 and
D2.Mxþ/ mice to assess MEOX2 protein levels. No significant
differences in MEOX2 protein levels were detected comparing
D2 and D2.Mxþ/ mice (Fig. 4A). Given that Meox2 is
associated with vascular remodeling including angiogenesis,
we then sought to determine if there were any differences in
the vasculature and surrounding basement membrane in the
ONH and retinas of young D2.Mxþ/ mice. No observable
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FIGURE 1. Meox2 is an early upstream regulator of genes that have significant fold changes of expression early in D2 glaucoma. (A) Upstream
regulator analysis on DE genes (FDR < 0.05) from stage 1c with a fold change greater than j1.5j was performed. This analysis determined Htatip2
(FC¼2.612, P¼3.653102), Nfatc1 (FC¼2.577, P¼1.803101), Rcan1 (FC¼2.537, P¼1.193101), Meox2 (FC¼2.373, P¼1.763106), and
Ikzf1 (FC¼ 2.365, P¼ 1.083 102) to be the top five regulatory transcription factors (TFs) at this stage. (B) Each of the top five regulatory TFs was
further analyzed to determine the predicted number of genes targeted. (34, 30, 18, 7, and 6 genes targeted, respectively). (C) To understand the
expression behavior of the top five regulatory TFs through the stages of D2 glaucoma, the fold change of expression over the seven stages was
analyzed. Each of the five TFs had a similar expression pattern; all but Meox2 first becomes significant at stage 1b (Meox2 at stage 1c), remaining
upregulated through stage 5. (D) Next, the number of mechanistic network associations for each TF was found. Nfatc1 and Meox2 were the only
upstream regulators that were associated with mechanistic networks (653 and 364 genes, respectively). (E) KEGG Pathway analysis of genes in the
Nfatc1 mechanistic network associations found pathways associated with inflammation, cell–cell interactions, and basement membrane turnover
(FDR < 0.05). (F) KEGG Pathway analysis of genes in the Meox2 mechanistic network associations found pathways associated with inflammation,
cell–cell interactions, and basement membrane turnover (FDR < 0.05).
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differences were identified in CD31, an endothelial cell marker,
and laminin, a basement membrane marker, in ONHs (Figs. 4B,
4C). Further, no significant differences were seen in retinal
vascular area comparing D2 and D2.Mxþ/ mice (Fig. 4D).
Analysis ofMeox2 also suggested a role in myeloid cell function
and neuroinflammation (Figs. 1–3); therefore we stained for
IBA1 (a marker of myeloid cells including resident microglia,
monocytes, and macrophages) in both the retina and ONH and
counted the number of positively stained cells. Again, we
found no significant differences in IBA1þmyeloid cell numbers
in the retina (Fig. 4E) or in the ONH (Figs. 4F, 4G) comparing
D2 and D2.Mxþ/mice. It is also of note that the morphology of
the myeloid cells was consistent with being in the sensing
(ramified) rather than the activated amoeboid state.
Meox2 Haploinsufficiency Increases the Numbers
of DBA/2J Eyes With Axon Damage
Upon finding no overt differences in vessel coverage or
myeloid cell number and morphology at a young age, we
functionally tested the effect of Meox2 haploinsufficiency in
D2 glaucoma. Cohorts of D2, D2.Mxþ/, D2.Gpnmbþ (D2.Gpþ),
and D2.GpþMxþ/ mice were established. D2 mice develop an
iris pigment disease resulting in OHT-dependent RGC death. In
our D2 colonies, the iris disease (iris pigment dispersion and
iris stromal atrophy) is evident at 6 months of age with OHT
apparent in significant numbers of eyes between 8 and 10
months. RGC loss occurs in few eyes at 9 months or younger
and many eyes between 10 and 12 months. Therefore, cohorts
were generated to track glaucoma-relevant phenotypes at 8,
10.5, and 12 months. Axon damage was also assessed in
cohorts of young (4 months) mice.
To determine whetherMeox2 haploinsufficiency affected the
normal progression of iris disease, slit-lamp examinations were
performed on eyes from mice of all genotypes at approximately
8 months (Fig. 5A). Clinical assessment found no significant
differences between eyes from D2 and D2.Mxþ/ mice,
suggesting that Meox2 haploinsufficiency did not affect the
normal progression of the D2 iris disease. Additionally, D2.Mxþ/
mice showed a similar age-dependent increase in IOP as D2
mice. There were no statistically significant differences in IOP
profiles comparing different genotypes within age and sex (Fig
5B). Furthermore, given the previously reported role for Meox2
in vascular development and maintenance, and the association
between blood pressure and glaucoma risk,53–55 blood pressure
was determined in D2 and D2.Mxþ/ mice. Meox2 haploinsuffi-
ciency did not affect blood pressure in either females or males
when compared to wild-type controls (Fig. 5C).
We next analyzed the degree of axon damage using PPD
staining of cross sections of optic nerves from all mice of all
cohorts. Each eye was assigned to one of three categories: no
axon damage, moderate axon damage, and severe axon damage
(Fig. 6A). This method of axon damage assessment allows us to
detect small but significant changes due to our ability to
include large numbers of optic nerves in the analysis, which is
necessary since D2 glaucoma is complex and asynchronous.
No eyes from young (4 months) mice of any genotype showed
any axon damage, indicating that Meox2 haploinsufficiency is
not sufficient to induce axon damage due to developmental
effects (Fig. 6B). At 8 months, approximately 13% of D2 males
had damage compared to 8% of D2.Mxþ/males, and 11% of D2
females compared to 36% of D2.Mxþ/ females (P¼ 0.443 and
P ¼ 4.583 109 respectively). At 10.5 months, approximately
67% of D2 males had axon damage compared to 77% of
D2.Mxþ/ males, and 64% of D2 females compared to 90% of
D2.Mxþ/ females (P ¼ 0.00835 and P ¼ 0.000558, respective-
ly). At 12 months, approximately 61% of D2 males had damage
compared to 67% of D2.Mxþ/ males, and 82% of D2 females
FIGURE 2. Gene ontology (GO) enrichment analysis of microarray data
of D2 glaucoma identifies Meox2 in GO terms associated with
angiogenesis. (A) Gene ontology enrichment analysis of microarray data
obtained by comparing D2 and D2.Gpþ controls found the –log(P value)
of the three most significant GO terms by Benjamini corrected P < 0.05
were ‘‘angiogenesis’’ (P ¼ 1.35 3 107), ‘‘positive regulation of
transcription from RNA pol II promoter’’ (P ¼ 8.97 3 107), and
‘‘transcription DNA-templated’’ (P¼ 4.263 105). The size of the circle
associated with the GO term corresponds with the number of genes
within that term (angiogenesis ¼ 123 genes, positive regulation of
transcription from RNA polymerase II promoter ¼ 399 genes,
transcription DNA-templated ¼ 690 genes). (B) The number of
differently expressed genes in the GO term ‘‘angiogenesis’’ at each
molecularly defined stage of glaucoma that are either up- or
downregulated at that stage. (C) Fold change of expression at each
molecularly defined state of glaucoma of a selection of genes from the
GO term ‘‘angiogenesis’’ and Meox2 was graphed. These genes are
related to basement membrane (Col4a1, Col4a2), blood clotting (Fn1),
cell proliferation (Pik3cg), breakdown of extracellular matrix (Mmp14),
and receptor for vascular endothelial growth factors (Flt4). Col4a1, Fn1,
and Pik3cg all become significantly upregulated at stage 1b and continue
through stage 5; Col4a2, Meox2, and Mmp14 all become significantly
upregulated at stage 1c and continue through stage 5; Vegfc and Flt4
become significantly upregulated in stage 1c; Vegfc remains significant
except for stage 4; Flt4 remains significant through stage 4.
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compared to 90% of D2.Mxþ/ females (P¼8.023106 and P¼
0.199, respectively) (Fig. 6C). Therefore, there were signifi-
cantly more eyes with either moderate or severe axon damage
in D2.Mxþ/ mice compared to D2 controls, suggesting that
Meox2 plays a beneficial role in response to OHT in D2
glaucoma.
Meox2 Haploinsufficiency Alters Vascular and
Myeloid Cell Responses in Aged D2 Mice
To begin to understand mechanism(s) by which Meox2
haploinsufficiency affects RGC axon damage we first assessed
MEOX2 protein levels in aged mice. Aged D2.Mxþ/ showed on
average a 44% reduction in MEOX2 protein levels compared to
aged D2 mice (Fig. 7A). Given its predicted role in vascular
health and inflammation (Figs. 1–3), we next assessed
vasculature in the ONH and retina. There were no overt
differences in vascular structures in the ONH of aged D2.Mxþ/
mice compared to aged D2 control mice (Fig. 7B). However,
significant differences were observed in the vascular area in
the retina. When compared to young controls, an overall
decrease in retinal vessel area was observed for both aged D2
and D2.Mxþ/ mice (Figs. 7C, 7D). However, this age-
dependent decrease was reduced in retinas from D2.Mxþ/
FIGURE 3. K-means analysis identifies Meox2 clustered with genes enriched for inflammatory pathways. (A) K-means clustering (k ¼ 6) of genes
differentially expressed through stages 2 through 5 identified five groups of genes with similar gene expression patterns across the stages (number
of genes: group 1¼ 700, group 2¼ 931, group 3¼ 477, group 4¼ 794, group 5¼ 455, and group 6¼ 780). Meox2 is in group 3. Group 6 contains
unclustered genes. (B) KEGG Pathway analysis on Meox2-containing group 3 reported ‘‘lysosome,’’ ‘‘phagosome,’’ ‘‘other glycan degradation,’’ and
‘‘osteoclast differentiation’’ as the most significant pathways by Benjamini corrected P < 0.05 (P¼9.693109, P¼4.243105, P¼2.213104, and
P ¼ 5.993 104, respectively). These enriched KEGG pathways are correlated with myeloid and inflammatory mechanisms. (C) GO enrichment
analysis on group 3 identified ‘‘extracellular exosome,’’ ‘‘lysosome,’’ and ‘‘plasma membrane’’ as most significant (Benjamini corrected P < 0.05).
(D) Expression of myeloid cells from enriched pathways matches Meox2 expression patterns. (E) Similarly, genes in glia–vascular-associated
pathways also match Meox2 expression patterns.
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compared to D2 mice. This resulted in significantly greater
vessel area in aged D2.Mxþ/ compared to aged D2 mice (Figs.
7C, 7D).
Finally, myeloid cell numbers were assessed. Although there
was no difference in myeloid cell numbers between aged D2
and D2.Mxþ/ retinas, there was a significant increase in
myeloid cell number between young and aged mice of both
genotypes (Fig. 7E). Further, Meox2 haploinsufficiency signif-
icantly affected myeloid cell numbers in the ONH. Specifically,
there was a significant increase in myeloid cells in D2 mice
from 4 months to 10.5 months. However, there was no
significant difference in myeloid cell numbers comparing 8
months to 10.5 months D2 mice. In contrast, for D2.Mxþ/
mice, there was a significant increase in myeloid cells
comparing both 4 months to 10.5 months and 8 months to
10.5 months (Figs. 7F, 7G). Therefore, these data support the
bioinformatic analyses that Meox2 plays a role in vascular and
myeloid cell changes in the retina and ONH during DBA/2J
glaucoma.
DISCUSSION
Here, we identified Meox2 as a potential driver of early
pathological changes in DBA/2J glaucoma through URA in IPA.
A role for Meox2 in glaucoma has not previously been
reported. Meox2 is an antennapedia-like homeobox-containing
transcription factor known to play a variety of important roles
during development.56,57 Mice deficient in Meox2 (Mx/) are
embryonic lethal while Meox2 haploinsufficient mice are
viable. In our previous study, Meox2 haploinsufficiency
exacerbated neurodegenerative phenotypes in a mouse model
relevant to Alzheimer’s disease.51 Here, Meox2 haploinsuffi-
ciency increased the number of eyes with moderate and severe
axon damage. This, and our previous study, suggest that Meox2
plays a beneficial role in multiple neurodegenerative diseases.
Our primary outcome measure in this study was axon damage.
We have previously shown that axon damage assessment
correlates closely with a decline in RGC function (by PERG)
and changes in axon transport.15,40–43 However, additional
FIGURE 4. Meox2 haploinsufficiency does not cause significant differences in blood vessel area or myeloid cell number in the ONH or retinas of
young D2 mice. (A) Western blot analysis on 4 months D2 (DBA/2J) and D2.Mxþ/ retinal tissue probing for MEOX2 protein and GAPDH
(glyceraldehyde 3-phosphate dehydrogenase, loading control). There was no significant reduction in MEOX2 between young D2 and D2.Mxþ/mice
(P¼ 0.8847). See Supplementary Figure S3A for full Western blot. (B) Immunofluorescence was performed on 4 months female ONH tissue of both
D2 and D2.Mxþ/ labeling for CD31 (endothelial cells) and laminin-111 (LAM, basement membrane). Representative images are shown. There were
no observable differences in expression in a sample of n¼ 6 per group. Scale bar: 50 lm. (C) Immunofluorescence was performed on 4 months
female retina tissue of both D2 and D2.Mxþ/ labeling for collagen-4 (COL4, basement membrane) and ionized calcium binding adapter molecule-1
(IBA1, myeloid cells). Representative images are shown. (D) COL4-labeled retinal vessel area was calculated in both 4 months D2 and D2.Mxþ/
mice. There was no significant difference in vessel area in a sample of n¼4 per condition (P¼0.7830). (E) IBA1-positive cells were counted in both
4 months D2 and D2.Mxþ/mice. There was no significant difference in myeloid cell number in a sample of n¼ 4 per condition (P¼ 0.8097). (F)
Immunofluorescence was performed on 4 months female ONH tissue of both D2 and D2.Mxþ/mice labeling for IBA1 and DAPI. (G) IBA1 and DAPI
double-positive cells were quantified as a function of area. There was no significant difference between 4 months D2 and D2.Mxþ/ females (P¼
0.1782). All P values were calculated using an unpaired t-test.
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studies are required to determine whether Meox2 haploinsuf-
ficiency has affected the functional state of RGCs. The effect on
axon damage was greater in female compared to male mice.
IOP elevation is known to occur earlier in female compared to
male D2 mice31 and might therefore be a contributing factor in
the greater effect of Meox2 haploinsufficiency observed in
female mice. However, no sex-specific genotype differences
were observed in IOP profiles, suggesting that the sex-specific
effect on axon damage may be independent of IOP.
The mechanisms by which Meox2 plays a potential
beneficial role in glaucoma are still to be elucidated. Gene
networks were identified that are predicted to be targeted by
Meox2. They were enriched for KEGG pathways associated
with cell proliferation, inflammation, extracellular matrix
interactions, and NVU-associated pathways. Also, analyses of
gene profiling data and k-means analysis predicted KEGG
pathways and GO terms relating to vascular responses (e.g.,
angiogenesis, basement membrane, and extracellular matrix
[ECM] maintenance) and neuroinflammation (e.g., myeloid cell
responses). We, and others, have shown reduced cerebrovas-
cular density in young Meox2 haploinsufficient mice.51,52
Contrary to the observations in the brain, Meox2 haploinsuffi-
ciency did not affect retinal vascular density at a young age.
This may be location (brain versus retina) or strain (C57BL/6
vs. DBA/2J) specific. These results provide further evidence of
potential differences in neurovascular responses in the retina
and brain during disease.
A significant decrease in retinal vascular area between
young and aged mice was observed, independent of genotype.
However, this age-dependent reduction in vascular area
appeared attenuated by Meox2 haploinsufficiency. Reduced
vascular area could be expected to be damaging and therefore
maintaining vascular area could be protective. However,
Meox2 haploinsufficiency increased the numbers of eyes with
severe optic nerve damage. Multiple factors might contribute
to this possible disconnect. The higher density in aged
D2.Mxþ/ compared to DBA/2J mice could be due to retinas
from D2.Mxþ/mice being at a more advanced stage of disease,
correlative with increased axon damage, leading to retinal
contraction resulting in increased retinal vascular area.
Alternatively, previous studies show that Meox2 is a regulator
of vascular cell proliferation,58–61 and angiogenesis has been
associated with injury response.62 An increase in vascular
proliferation or angiogenesis, on a background of age-
dependent decrease in vascular density, could account for
the increase in D2.Mxþ/ compared to DBA/2J mice. These
new vessels may not be fully functional. Finally, an increase in
basement membrane deposition in D2.Mxþ/ mice but not in
DBA/2J mice would also lead to an increase in vessel area
(vessels were visualized using an antibody to collagen 4). This
increase in basement membrane deposition may result in
reduced function of the retinal vessels, accelerating RGC
damage and death.
FIGURE 5. Meox2 haploinsufficiency does not affect iris pigment dispersion disease progression or intraocular pressure in DBA/2J mice. (A)
Representative slit-lamp images from clinical examinations of 9 months mice. Each row contains three images from the same eye (left column, broad
beam illumination; middle column, relative dimensions of the anterior chamber; right column, transillumination). There were no observable
differences in iris disease progression from D2 and D2.Mxþ/ females (n¼30, 22, respectively) and males (n¼16, 18, respectively) at 9 months. (B)
IOP changes relative to age in D2 glaucoma. Here, we analyzed age-related distribution of IOP in D2 and D2.Mxþ/mice. No significant difference
was found between D2 and D2.Mxþ/mice within sex and age. Dot blots and standard error mean bars were generated using Prism v7.05. Each dot
represents the average IOP of a triplicate reading of one eye within one experiment. The dotted line at 21 mm Hg represents a threshold of
glaucoma-relevant IOP (8 months: female D2 n¼27, D2.Mxþ/n¼39; male D2 n¼33, D2.Mxþ/ n¼40) (10.5 months: female D2 n¼24, D2.Mxþ/
n ¼ 30; male D2 n ¼ 20, D2.Mxþ/ n ¼ 46) (12 months: female D2 n ¼ 20, D2.Mxþ/ n ¼ 22; male D2 n ¼ 22, D2.Mxþ/ n ¼ 46). (C) Meox2
haploinsufficiency did not affect blood pressure when compared to wild-type controls; however, there is a significant difference between DBA/2J
females and males at 8 months of age (P ¼ 0.0199).
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FIGURE 6. Meox2 haploinsufficiency accelerates axon damage in D2 mice. (A) Representative images of DBA/2J optic nerve cross sections stained
with paraphenylenediamine (PPD) showing the previously validated morphologic categories of axon damage (NOE, no axonal damage or early
molecular changes; MOD, moderate damage; SEV, severe damage). Scale bar: 25 lm. (B) Distributions of axon damage of male and female D2 and
D2.Mxþ/mice aged 4, 8, 10.5, and 12 months. (C) Distributions of optic nerve damage show a significant difference between D2 and D2.Mxþ/ eyes
in females at 8 months (v2 values ¼ 4.579283 1009, 0.015375192, and 6.726813 1026, respectively), a significant difference between D2 and
D2.Mxþ/ in females and males at 10.5 months (v2 values ¼ 0.000557957, 0.008348159, 0.01096447, and 0.011528155, respectively), and a
significant difference between D2 and D2.Mxþ/ in females and males at 12 months (v2 values¼ 8.023933 1006, 0.039435742, and 0.000221381,
respectively). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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FIGURE 7. Aged Meox2 haploinsufficient mice have reduced vessel density in the retina and increased myeloid cells in the ONH. (A) Western blot
analysis on 10.5 months D2 (DBA/2J) and D2.Mxþ/ retinal tissue probing for MEOX2 protein and GAPDH (loading control). There was a 44.4%
reduction in MEOX2 protein levels between aged D2 and D2.Mxþ/ mice (P¼ 0.0026). See Figure S3B for full blot. (B) Immunofluorescence was
performed on 10.5 months female ONH tissue of both D2 and D2.Mxþ/ labeling for CD31 (endothelial cells) and laminin-111 (LAM, basement
membrane). Representative images are shown. There was no observable difference in expression in a sample of n¼ 6 per condition. Scale bar: 50
lm. (C) Immunofluorescence was performed on 10.5 months female retina tissue of both D2 and D2.Mxþ/ labeling for collagen-4 (COL4, basement
membrane) and IBA1 (myeloid cells). Representative images are shown. (D) COL4-labeled retinal vessel area was calculated in both 4 months and
10.5 months D2 and D2.Mxþ/mice (young data reproduced from Fig. 4D). There was a significant decrease between 4 months and 10.5 months in
both D2 and D2.Mxþ/mice (P¼ 0.0005 and P¼ 0.0244, respectively). However, there was also a significant increase in vessel area between 10.5
months D2.Mxþ/ and D2 mice (P¼0.0133). (E) IBA1-positive cells were counted in the retinas of both 4 months and 10.5 months D2 and D2.Mxþ/
mice. There was no significant difference in myeloid cell number in a sample of n¼7 per condition between 10 months D2 and D2.Mxþ/mice (P¼
0.9615). However, there was significant increase between 4 months and 10.5 months in both D2 and D2.Mxþ/mice (P¼ 0.0319 and P¼ 0.0248,
respectively). (F) Immunofluorescence was performed on 10.5 months female ONH tissue of both D2 and D2.Mxþ/ mice labeling for IBA1 and
DAPI. (G) IBA1 and DAPI double-positive cells were quantified as a function of area. There was no significant difference between 10.5 months D2
and D2.Mxþ/ females (P¼0.1782). There is a significant increase in IBA1þDAPIþ cells in D2 and D2.Mxþ/ONHs from 4 to 10.5 months (P¼0.0017
and P¼< 0.0001, respectively). Additionally, there is a significant increase in D2.Mxþ/ONHs from 8 to 10.5 months (P¼0.0148). All P values were
found using a 2-way ANOVA.
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Eye diseases such as age-related macular degeneration,
choroidal neovascularization, and diabetic retinopathy have
been correlated with angiogenesis and vascular regulation by
glial cells.63,64 Neurovascular dysfunction and associated glial
responses have also been a topic of much focus in
glaucoma.16,65,66 Interestingly, we recently showed that
metabolic stress is a key component of D2 glaucoma.42
Vascular health is strongly linked to metabolic health, so
understanding the interactions between vascular responses
and metabolic stress in glaucoma is critical.
In the ONH microarray data, Meox2 expression increased at
the same molecular stage of disease (prior to axon damage) as
laminins, collagens, matrix metalloproteinases (MMPs), and
tissue inhibitors of MMPs (TIMPs); the cell types secreting
these molecules work congruently to maintain NVU func-
tion.67 Quantifying vasculature in the ONH was challenging
due to the low density of vasculature in this region and an
apparent variability between eyes—even from controls such as
the D2.Gpþ mice. Therefore, no observable differences were
identified in laminin or CD31 in the ONHs of D2 and D2.Mxþ/
mice. This could be because the antibody used was a pan-
laminin that binds primarily LAMA1. The gene expression data
show Lamb2 and Lamc1 being upregulated. Therefore,
immunoassays for specific laminin monomers and collagens
could be more informative of NVU changes in the ONH in
glaucoma, particularly considering the observation that retinal
vasculature is altered. In support of a role of ONH vascular in
glaucoma, a recent study by Zhu and colleagues68 used C57BL/
6 mice to show that blood vessels in the ONH thicken with age
and after induction of high IOP in young mice. This type of
analysis is more challenging to perform in D2 mice given the
variable age of onset of IOP elevation.
The question of beneficial versus damaging immune
responses has led to predictions of early inflammatory
signaling being protective to RGCs following axon injury and
prolonged IOP elevation evolving into a chronic and damaging
inflammation.13,69–71 Specific immune-like functions have been
found to be both protective and damaging in glaucoma.15,72–74
Disruption of the endothelin system and complement compo-
nent C1qa reduced the numbers of eyes with axon damage in
D2 mice, suggesting they play a damaging role.14 In contrast,
knocking out complement component C3 increased the
numbers of eyes with glaucoma, suggesting it plays a beneficial
role.15 Like C3, Meox2 appears to exert a beneficial response
mediated at least in part through immune responses—in this
case in myeloid cells. Interestingly, a recent paper showed that
knocking down C3 in RGCs using a viral approach appeared to
protect from RGC loss, suggesting an additional layer of
complexity whereby cell type–specific responses of the same
gene/pathways may have opposing effects at different stages in
glaucoma.74
In addition to changes in the vascular area, Meox2 appears
to also impact myeloid cell numbers. In this study we refer to
myeloid cell responses, not microglial responses, as mono-
cytes/macrophage-like cells infiltrate from the periphery
during early stages in DBA/2J glaucoma.32,43 Anti-IBA1, the
antibody used to label myeloid cells, does not distinguish
resident microglia from infiltrating monocytes/macrophages.
The role of these different myeloid cell subtypes in glaucoma is
not clear. Microglia activation in response to elevated IOP has
been seen in many studies, and early microglia changes, such
as microgliosis prior to IOP damage, has been reported to
correlate with late severity of nerve pathology.75,76 Therefore,
in combination, these studies chronicle a close relation
between elevated IOP and microglial activation. A similarly
complex relationship between disease insult and microglia
activation is being reported for other neurodegenerative
diseases.77 For instance, in Alzheimer’s Disease, microglia
may execute a beneficial response to clear amyloid78 but also
aberrantly prune synapses.79 Multiple studies are now using
single-cell profiling approaches to define subtypes of microglia
and other myeloid cells (monocytes/macrophages) to develop
strategies to target damaging but not beneficial cells.80 Similar
approaches should be employed for glaucoma. Understanding
the relationship between vascular health and myeloid respons-
es will also be important to better inform potential strategies
for treatments for glaucoma.
D2 mice develop glaucoma due to mutations in Gpnmb and
Tyrp1 that cause the iris disease that is necessary for IOP
elevation.29,30 This is evident in the D2.Gpþ strain that
develops neither high IOP nor RGC loss. This allowed us to
assess Meox2 function in the absence of IOP elevation. Meox2
haploinsufficiency did not cause iris disease, increased IOP, or
axonal damage in D2.Gpþ mice (Supplementary Fig. S1).
Myeloid cell numbers did not change in D2.Gpþ or
D2.GpþMxþ/ mice between 4 months and 10.5 months.
However, there are fewer myeloid cells when comparing 10.5
months D2.Gpþ and D2.GpþMxþ/ mice (Supplementary Fig.
S2). This suggests that Meox2 may play a role in myeloid cell
health, maintenance, or turnover during aging. For instance,
there may be an increase in the rate of myeloid cell turnover in
D2.GpþMxþ/ compared to D2.Gpþ mice. In this study, we
assessed mice up to only 12 months—considered midlife in
humans. Additional analyses of older mice would be required
to fully determine whether Meox2 plays a key role in myeloid
cell maintenance and turnover.
In summary, we have identified Meox2 as a potential
regulator of early, beneficial stages of glaucoma in DBA/2J
mice. We predict that its effect is mediated in part through
modified vascular and myeloid cell responses. This work
provides further evidence that the earliest changes in response
to IOP elevation are beneficial and that enhancing these
responses may delay onset of visual defects in human
glaucomas.
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